Work at Laekna Therapeutics Shanghai Co. Ltd. has led to the discovery of a potent leukocyte immunoglobulin-like receptor subfamily B member 1/2 (LILRB1/LILRB2) antagonistic bispecific antibody, LAE-111, with improved antitumor activity.
CLDN18 is a cell surface membrane protein involved in the formation of tight junctions, and the expression of its CLDN18.2 isoform has been observed in pancreatic, gastric and esophageal tumors.
Sirpant Immunotherapeutics Inc.’s lead product candidate, Sirpant-M (SI-101), has been awarded U.S. orphan drug designation for the treatment of T-cell lymphoma.
Researchers from Nkgen Biotech Inc. have developed an anti-HER2 CAR NK cell therapy, named SNK-02, as a potential immunotherapeutic for HER2-overexpressing tumors. SNK-02 was tested in a xenografted murine model of cancer.
Certain types of human papillomavirus (HPV), named high-risk types, are known to be clearly associated with 60% of invasive cervical cancer cases. Prophylactic HPV vaccines are highly effective, but there is a need for new treatment options other than surgery.
Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a strategic collaboration with Genequantum Healthcare (Suzhou) Co. Ltd. to advance the early discovery of next-generation bioconjugates.
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary Receptorscan platform. It is being developed for the treatment of human papillomavirus 16 (HPV16)-positive solid tumors. The therapeutic TCR in TSC-200-A0201 was introduced into a transposon vector, with the resulting TCR T therapy product being a mixture of cytotoxic and helper T cells, both reprogrammed to recognize HPV16+ HLA-A*02:01+ cells.
Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung cancer and bladder cancer, but limited expression in normal tissues.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.
RSS
